Business

Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Dr. Ian Y. Liu as Senior Vice President, Global Head of Legal. Dr. Liu will be based in the U.S. and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

articleHbm Holdings Ltd.March 10, 20253/company/hbm-holdings-ltd/news/harbour-biomed-appoints-dr-ian-y-liu-as-global-head-of-legal
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

About this update from Hbm Holdings Ltd.

[{"type":"text","content":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Dr. Ian Y. Liu as Senior Vice President, Global Head of Legal. Dr. Liu will be based in the U.S. and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.","length":500,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Harbour BioMed)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Harbour BioMed)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":159,"url":"https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QANxnzzeBFHKxcqoWHourA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a","width":400,"height":159}},"href":"https://mma.prnewswire.com/media/1096360/HB_for_email_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"With his extensive legal expertise and industry experience, Dr. Liu will oversee business development transactions, ensuring legal and regulatory compliance while facilitating seamless execution to safeguard the company's interests. He will also lead the company's global intellectual property strategy. Additionally, Dr. Liu will take full responsibility for managing U.S.-related legal affairs, including prosecution and litigation of all legal cases, protecting the company's business operations in the region and supporting its strategic growth in the U.S. market.","length":580,"tagName":"p"},{"type":"text","content":"Before joining Harbour BioMed, Dr. Liu worked at renowned law firms, including Finnigan, Henderson, Farabow, Garrett & Dunner, LLP, and K&L Gates, LLP, where he gained extensive experience in patent applications, litigation, and due diligence. In the corporate legal affairs sector, he held key positions such as Head of Legal and Governmental Affairs at Simcere Pharmaceutical, demonstrating exceptional ability in handling complex legal matters and commercial negotiations.","length":483,"tagName":"p"},{"type":"text","co...

More updates from Hbm Holdings Ltd.

Harbour BioMedIan Y. Liubiopharmaceutical companylegal affairsantibody therapeuticsJingsong Wangindustry experienceDr